Atlantic Lipid Lowering Treatment Optimization Program

NARecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Familial HypercholesterolemiaLipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaApolipoprotein B 100, Familial DefectiveHigh Density Lipoprotein DeficiencyLow-Density-Lipoid-Type Hyperlipoproteinemia
Interventions
OTHER

Supportive care

The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.

Trial Locations (2)

07066

NOT_YET_RECRUITING

Atlantic Medical Group, Clark

07081

RECRUITING

Atlantic Medical Group, Springfield

Sponsors
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Atlantic Health System

OTHER